Injectable filling material as well as preparation method and application thereof

Through the combination of specific crosslinked hyaluronic acid gel and polyester microspheres, the problem of rapid degradation of crosslinked hyaluronic acid gel and slow onset of polyester microspheres is solved, and the rapid onset and long-term effect is achieved. Injection of filler materials ensures injection safety and aesthetics and meets mechanical performance requirements.

CN119055832APending Publication Date: 2024-12-03BEIJING MEIYAN SPACE BIOMEDICINE CO LTD
View PDF 0 Cites 3 Cited by

Patent Information

Application Number
CN202411209750.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-30
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

In the prior art, crosslinked hyaluronic acid gel degrades quickly in the body and has a short effect time. Polyester microsphere filling materials take effect slowly and easily lead to inflammatory reactions during injection, which cannot meet the rapid onset and long-term effect at the same time. , aesthetics and safety requirements.

Method used

Using a combination of specific crosslinked hyaluronic acid gels and polyester microspheres, an injectable filler material is prepared by adjusting the ratio of HA to polyester microspheres and the elastic modulus of crosslinked hyaluronic acid gels to ensure the material Good dispersion in the body, low injection pushing force, low cytotoxicity, and appropriate mechanical properties.

Benefits of technology

Achieves rapid onset and long-term injectable filling material. Polyester microspheres have good dispersion in the system and are not prone to needle blocking or inflammation during injection. They are safe to use, natural filling effect, high aesthetics, and mechanical properties. Meet the requirements.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119055832A_ABST
    Figure CN119055832A_ABST
Patent Text Reader

Abstract

The invention discloses an injectable filling material and a preparation method and application thereof. The injectable filling material comprises hyaluronic acid substances and polyester microspheres; the hyaluronic acid substance is a cross-linked hyaluronic acid gel, or consists of a cross-linked hyaluronic acid gel and a non-cross-linked hyaluronic acid substance; the mass ratio of HA in the hyaluronic acid substances to the polyester microspheres is 1: (2-25); the mass ratio of the HA to the non-crosslinked hyaluronic acid substance in the crosslinked hyaluronic acid gel is 1: (0-0.5); the elastic modulus G of the cross-linked hyaluronic acid gel under 1Hz is 100 to 600Pa; and the particle size D50 of the cross-linked hyaluronic acid gel is 200-500 [mu] m. The prepared injectable filling material has the advantages of fast effectiveness and long effectiveness, good dispersion of the polyester microspheres, low possibility of needle blockage or inflammation induction and the like during injection, small injection pushing force and cytotoxicity, high use safety, natural filling effect and high aesthetic degree, and the mechanical properties of the injectable filling material meet the requirements.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of medical aesthetics, and in particular to an injectable filling material and a preparation method and application thereof. Background Art

[0002] Sodium hyaluronate is a naturally occurring degradable polysaccharide with ideal biocompatibility and wrinkle correction effects, and is widely used in the field of medical beauty. However, sodium hyaluronate degrades quickly in the body, has a short retention time, and requires frequent injections, which brings inconvenience to those seeking beauty. Although cross-linked hyaluronic acid can overcome the problem of rapid degradation of sodium hyaluronate to a certain extent, the degree of cross-linking has a great impact on product performance. If it is not properly controlled, it will lead to limited effect on improving the duration of effect in the body, or too high elastic modulus, which will lead to unnatural filling effect, stiffness, and difficulty in dispersion after injection, resulting in inflammatory response.

[0003] After injection, polyester microsphere filling materials will induce fibroblast proliferation and myofibroblast differentiation, promote the synthesis of a large amount of collagen, and thus make up for the defect of collagen loss. Polyester microsphere filling materials have good cosmetic effects and a long duration of action. However, polyester microsphere filling materials take effect slowly and cannot be effective immediately after injection. In addition, polyester microsphere filling materials are hydrophobic materials. When the injection concentration is high, it is easy to cause adverse reactions such as inflammation. It is easy to accumulate during injection, resulting in a large injection pushing force and increased injection pain. If the injection concentration is reduced, the effect of promoting collagen regeneration is not ideal.

[0004] Therefore, there is an urgent need in the art to develop an injectable filling material with rapid onset of action, lasting cosmetic effect, good biocompatibility, ideal stability, small injection pushing force, high safety in use, natural filling effect, and high aesthetics. Summary of the invention

[0005] The technical problem to be solved by this application is to overcome the defects of the prior art that the cross-linked hyaluronic acid gel degrades quickly in vivo, has a short duration of effect, or has an excessively high elastic modulus, an unnatural filling effect, a stiff feeling, is not easy to disperse after injection, and produces an inflammatory reaction; the polyester microsphere filling material has a slow onset, is prone to accumulation when the injection concentration is high, resulting in a large pushing force, a strong injection pain, and is prone to causing adverse reactions such as inflammation; when the injection concentration is low, the effect of promoting collagen production is not ideal, and an injectable filling material and its preparation method and application are provided. The injectable filling material prepared in this application includes specific cross-linked hyaluronic acid gel and polyester microspheres, which meet the requirements of rapid onset and long-term effect at the same time. The polyester microspheres have good dispersibility in the system, are not prone to problems such as needle blockage or induced inflammation during injection, and have low injection pushing force and cytotoxicity. It is safe to use, and the mechanical properties also meet the requirements. The filling effect is natural and the aesthetics are high.

[0006] This application solves the above technical problems through the following technical solutions.

[0007] The present application provides an injectable filling material, which includes a hyaluronic acid substance and polyester microspheres; the hyaluronic acid substance is a cross-linked hyaluronic acid gel, or is composed of a cross-linked hyaluronic acid gel and a non-cross-linked hyaluronic acid substance;

[0008] Among them, the mass ratio of HA in the hyaluronic acid substance to the mass ratio of the polyester microspheres is 1:(2-25); the mass ratio of HA in the cross-linked hyaluronic acid gel to the non-cross-linked hyaluronic acid substance is 1:(0-0.5); the elastic modulus G` of the cross-linked hyaluronic acid gel at 1 Hz is 100-600 Pa; the particle size D50 of the cross-linked hyaluronic acid gel is 200-500 μm.

[0009] In some embodiments, the mass ratio of HA in the hyaluronic acid substance to the mass ratio of the polyester microspheres is 1:(10-25), preferably 1:(10-17), for example 1:3, 1:5, 1:7, 1:9, 1:11, 1:13, 1:15, 1:17, 1:19, 1:21, 1:23 or 1:25.

[0010] In some embodiments, the mass ratio of HA in the cross-linked hyaluronic acid gel to the non-cross-linked hyaluronic acid substance is 1: (0-0.4), preferably 1: (0-0.3), for example 1: 0.05, 1: 0.07, 1: 0.1, 1: 0.15, 1: 0.2, 1: 0.25, 1: 0.3, 1: 0.35, 1: 0.4, 1: 0.45 or 1: 0.5. According to the convention in the art, the mass of HA in the cross-linked hyaluronic acid gel is the total content of HA in the cross-linked hyaluronic acid gel, and the total content is determined by referring to the method in Appendix C of YY / T 0962-2021 "Cross-linked Sodium Hyaluronate Gel for Plastic Surgery".

[0011] In some embodiments, the concentration of HA in the cross-linked hyaluronic acid gel is 15 to 30 mg / g, preferably 18 to 25 mg / g, for example 15 mg / g, 17 mg / g, 19 mg / g, 20 mg / g, 21 mg / g, 23 mg / g or 25 mg / g. According to the convention in the art, the concentration of HA in the cross-linked hyaluronic acid gel is the mass ratio of the total content of HA in the cross-linked hyaluronic acid gel to the cross-linked hyaluronic acid gel; the total content of HA in the cross-linked hyaluronic acid gel is determined by referring to the method in Appendix C of YY / T 0962-2021 "Cross-linked Sodium Hyaluronate Gel for Plastic Surgery".

[0012] In some embodiments, the elastic modulus G' of the cross-linked hyaluronic acid gel at 1 Hz is 100-500 Pa, preferably 250-350 Pa, for example 100 Pa, 150 Pa, 200 Pa, 250 Pa, 300 Pa, 320 Pa, 350 Pa, 400 Pa, 450 Pa, 500 Pa, 550 Pa or 600 Pa.

[0013] In some embodiments, the viscosity modulus G`` of the cross-linked hyaluronic acid gel at 1 Hz is 20 to 100 Pa, preferably 20 to 40 Pa, for example 20 Pa, 25 Pa, 30 Pa, 35 Pa, 40 Pa, 45 Pa, 50 Pa, 55 Pa, 60 Pa, 65 Pa, 70 Pa, 75 Pa, 80 Pa, 85 Pa, 90 Pa, 95 Pa or 100 Pa.

[0014] In some embodiments, the cross-linked hyaluronic acid gel is -1 The shear viscosity η at the shear rate is 40 to 100 Pa·s, for example, 40 Pa·s, 45 Pa·s, 50 Pa·s, 55 Pa·s, 60 Pa·s, 65 Pa·s, 70 Pa·s, 75 Pa·s, 80 Pa·s, 85 Pa·s, 90 Pa·s, 95 Pa·s or 100 Pa·s.

[0015] In some embodiments, the particle size D50 of the cross-linked hyaluronic acid gel is 250-350 μm, for example 200 μm, 220 μm, 240 μm, 260 μm, 280 μm, 300 μm, 320 μm, 340 μm, 360 μm, 380 μm, 400 μm, 420 μm, 440 μm, 460 μm, 480 μm or 500 μm.

[0016] In some embodiments, the particle size D10 of the cross-linked hyaluronic acid gel is 100-200 μm, preferably 140-170 μm, for example 100 μm, 120 μm, 140 μm, 160 μm, 180 μm or 200 μm.

[0017] In some embodiments, the particle size D90 of the cross-linked hyaluronic acid gel is 400-700 μm, preferably 400-600 μm, for example 400 μm, 450 μm, 500 μm, 550 μm, 600 μm, 650 μm or 700 μm.

[0018] In some embodiments, the non-cross-linked hyaluronic acid substance is non-cross-linked hyaluronic acid and / or non-cross-linked hyaluronate, wherein the non-cross-linked hyaluronate is selected from at least one of non-cross-linked sodium hyaluronate, non-cross-linked potassium hyaluronate, non-cross-linked calcium hyaluronate and non-cross-linked zinc hyaluronate.

[0019] In some embodiments, the molecular weight of the non-cross-linked hyaluronic acid substance is 10 WDa to 300 WDa, preferably 50 to 200 WDa, for example 130 WDa.

[0020] In some embodiments, the polyester microspheres have a particle size of 20-50 μm accounting for more than 80%, preferably more than 90%.

[0021] In some embodiments, the particle size D50 of the polyester microspheres is 20-50 μm, preferably 30-40 μm.

[0022] In some embodiments, the material of the polyester microspheres is selected from at least one of polylactic acid, polycaprolactone, polyhydroxyalkanoate, PLA-PEG block copolymer, PLA-PEG-PLA block copolymer and PCL-PEG block copolymer.

[0023] In some embodiments, the injectable filling material further includes a buffer and / or an anesthetic.

[0024] The buffer may be a buffer acceptable in the medical field, preferably a phosphate buffer.

[0025] Preferably, the phosphate buffer comprises dihydrogen phosphate and dihydrogen phosphate. More preferably, the dihydrogen phosphate is selected from disodium hydrogen phosphate and / or dipotassium hydrogen phosphate. More preferably, the dihydrogen phosphate is selected from sodium dihydrogen phosphate and / or potassium dihydrogen phosphate.

[0026] Wherein, the osmotic pressure of the buffer solution is 220-320 mOsm / L.

[0027] Wherein, the pH value of the buffer solution is 6.0-8.0.

[0028] Wherein, the anesthetic is selected from at least one of lidocaine hydrochloride, lidocaine carbonate, tetracaine, prilocaine, procaine, mepivacaine and bupivacaine.

[0029] The mass percentage of the anesthetic to the injectable filling material is 0.1% to 0.5%, for example, 0.1%, 0.2%, 0.3%, 0.4% or 0.5%.

[0030] In some embodiments, the method for preparing the polyester microspheres comprises the following steps: assembling the polyester microsphere materials described above into microspheres by using an emulsified solvent volatilization method.

[0031] In a preferred embodiment, the method for preparing the polyester microspheres comprises the following steps: the organic phase comprises the material of the polyester microspheres and an organic solvent; the aqueous phase comprises a surfactant and water; the organic phase and the aqueous phase are mixed, emulsified, and solidified to obtain the polyester microspheres.

[0032] Wherein, the organic solvent is selected from halogenated alkane solvents and / or ester solvents.

[0033] Preferably, the halogenated alkane solvent is a chlorinated alkane solvent, more preferably selected from dichloromethane and / or chloroform.

[0034] Preferably, the ester solvent is C2-C6 alkyl acetate, more preferably ethyl acetate.

[0035] The mass volume ratio of the polyester microsphere material to the organic solvent is 80-350 g / L, for example, 200 g / L or 250 g / L.

[0036] The volume ratio of the organic phase to the aqueous phase is 1:(3-20), preferably 1:(5-15), for example 1:10.

[0037] Wherein, the surfactant is polyvinyl alcohol, preferably polyvinyl alcohol 1788.

[0038] The mass volume ratio of the surfactant to the water is 8 to 45 g / L, for example, 15 g / L, 20 g / L, 25 g / L, 30 g / L or 35 g / L.

[0039] Wherein, the viscosity of the aqueous phase is 4 to 25 mPa·s, for example, 7.5 mPa·s, 9 mPa·s, 11 mPa·s, 13 mPa·s, 15 mPa·s, 17 mPa·s, 19 mPa·s, 21 mPa·s or 23 mPa·s.

[0040] Wherein, the water is purified water.

[0041] Wherein, the preparation method of the water phase comprises the following steps: mixing the surfactant and the water.

[0042] During the preparation of the aqueous phase, the mixing can be performed under stirring conditions as is conventional in the art, preferably mechanical stirring as is conventionally used in the art.

[0043] During the preparation of the aqueous phase, the mixing temperature is 20-80°C, for example 60°C.

[0044] Wherein, the emulsification method includes mechanical stirring emulsification method, membrane emulsification method or homogenization emulsification method.

[0045] The curing method includes a reduced pressure volatilization method and / or an air flow blowing method. According to the conventional art, the purpose of the curing is to remove the organic solvent in the system and promote the curing of the emulsion into microspheres.

[0046] In a preferred embodiment, the material of the polyester microspheres is PLA-PEG-PLA block copolymer.

[0047] The number average molecular weight of the PLA-PEG-PLA block copolymer is 40,000 to 130,000, preferably 40,000 to 120,000, more preferably 40,000 to 90,000, such as 50,000, 60,000, 70,000 or 80,000.

[0048] The number average molecular weight of PEG in the PLA-PEG-PLA block copolymer is 100-800, preferably 200-800, for example, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750 or 800.

[0049] Wherein, the PLA in the PLA-PEG-PLA block copolymer is selected from at least one of L-polylactic acid, D-polylactic acid and racemic polylactic acid, preferably L-polylactic acid.

[0050] The preparation method of the PLA-PEG-PLA block copolymer comprises the following steps: in an inert atmosphere and under the action of a catalyst, polyethylene glycol and lactide undergo a polymerization reaction to obtain the PLA-PEG-PLA block copolymer; wherein the number average molecular weight of the polyethylene glycol is 100 to 800, and the mass ratio of the polyethylene glycol to the lactide is (1 to 20):1000.

[0051] During the preparation of the PLA-PEG-PLA block copolymer, the number average molecular weight of the polyethylene glycol is 200-800, preferably 400-800, for example 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750 or 800.

[0052] During the preparation of the PLA-PEG-PLA block copolymer, the mass ratio of the polyethylene glycol to the lactide is (3-20):1000, preferably (3-10):1000.

[0053] During the preparation of the PLA-PEG-PLA block copolymer, the lactide is selected from L-lactide and / or D-lactide.

[0054] During the preparation of the PLA-PEG-PLA block copolymer, the inert atmosphere is selected from nitrogen and / or an inert gas. Preferably, the inert gas is selected from helium and / or argon.

[0055] In the preparation process of the PLA-PEG-PLA block copolymer, the catalyst is selected from a tin catalyst and / or a zinc catalyst. Preferably, the tin catalyst is selected from at least one of dibutyltin diacetate, dibutyltin dibenzoate, tri-n-butyl methoxytin, dibutyltin dilaurate, stannous octoate, stannous octoate and stannous isooctanoate. Preferably, the zinc catalyst is selected from zinc lactate and / or zinc acetate.

[0056] During the preparation of the PLA-PEG-PLA block copolymer, the molar ratio of the catalyst to the lactide is (10 -5 ~10 -3 ): 1, preferably (10 -4 ~10 -3 ): 1, for example 4.6×10 -4 :1.

[0057] In the preparation process of the PLA-PEG-PLA block copolymer, the polymerization reaction is melt polymerization. Preferably, the melt polymerization specifically comprises the following steps: under the protection of an inert atmosphere, adding the polyethylene glycol and the catalyst to the molten lactide to carry out a polymerization reaction.

[0058] During the preparation of the PLA-PEG-PLA block copolymer, the polymerization reaction temperature is 110-180°C, preferably 125-165°C, such as 135°C.

[0059] During the preparation of the PLA-PEG-PLA block copolymer, the polymerization reaction time can be a conventional time for such reactions in the art, preferably 4 to 24 hours.

[0060] In the preparation process of the PLA-PEG-PLA block copolymer, the polymerization reaction may be followed by at least one of recrystallization, collecting precipitates, washing and drying.

[0061] In some embodiments, the preparation method of the cross-linked hyaluronic acid gel includes the following steps: mixing a cross-linking agent, a non-cross-linked hyaluronic acid substance and an alkaline aqueous solution, and obtaining the cross-linked hyaluronic acid gel through a cross-linking reaction; wherein the cross-linking agent is a cross-linking agent containing at least two epoxy groups; the volume mass ratio of the cross-linking agent to the non-cross-linked hyaluronic acid substance is 1.5 to 25 μL / g; the mass ratio of the non-cross-linked hyaluronic acid substance to the alkaline aqueous solution is (0.16 to 0.4): 1; the mass percentage of alkaline substances in the alkaline aqueous solution is 0.8% to 2%.

[0062] During the preparation of the cross-linked hyaluronic acid gel, the cross-linking agent is selected from a cross-linking agent containing two epoxy groups, preferably selected from at least one of 1,4-butanediol diglycidyl ether, ethylene glycol diglycidyl ether, neopentyl glycol diglycidyl ether, polyethylene glycol diglycidyl ether, polypropylene glycol diglycidyl ether and poly(dimethylsiloxane) diglycidyl ether.

[0063] During the preparation of the cross-linked hyaluronic acid gel, the volume mass ratio of the cross-linking agent to the non-cross-linked hyaluronic acid substance is 5-25 μL / g, preferably 10-20 μL / g, for example 2 μL / g, 4 μL / g, 6 μL / g, 8 μL / g, 10 μL / g, 12 μL / g, 15 μL / g, 18 μL / g, 20 μL / g, 22 μL / g or 25 μL / g.

[0064] In the preparation process of the cross-linked hyaluronic acid gel, the non-cross-linked hyaluronic acid substance is selected from non-cross-linked hyaluronic acid and / or non-cross-linked hyaluronate. Preferably, the non-cross-linked hyaluronate is selected from at least one of non-cross-linked sodium hyaluronate, non-cross-linked potassium hyaluronate, non-cross-linked calcium hyaluronate and non-cross-linked zinc hyaluronate.

[0065] During the preparation of the cross-linked hyaluronic acid gel, the molecular weight of the non-cross-linked hyaluronic acid substance is 50WDa-200WDa, preferably 60WDa-200WDa, for example 60WDa-70WDa, 130WDa or 150WDa.

[0066] During the preparation of the cross-linked hyaluronic acid gel, the mass ratio of the non-cross-linked hyaluronic acid substance to the alkaline aqueous solution is (0.18-0.4):1, preferably (0.2-0.4):1, for example 0.33:1.

[0067] In the preparation process of the cross-linked hyaluronic acid gel, the alkaline aqueous solution is selected from at least one of a sodium hydroxide aqueous solution, a potassium hydroxide aqueous solution, a sodium carbonate aqueous solution and a sodium bicarbonate aqueous solution.

[0068] During the preparation of the cross-linked hyaluronic acid gel, the water in the alkaline aqueous solution includes at least one of deionized water, distilled water, purified water and water for injection.

[0069] In the preparation process of the cross-linked hyaluronic acid gel, the mixing includes the following steps: mixing the cross-linking agent with the alkaline aqueous solution once to obtain material A; and mixing the material A with the non-cross-linked hyaluronic acid substance for a second time.

[0070] Preferably, the primary mixing and / or the secondary mixing may be performed under stirring conditions according to the conventional art.

[0071] Preferably, the time for the primary mixing and / or the secondary mixing may be conventional in the art, generally sufficient to mix the components uniformly.

[0072] During the preparation of the cross-linked hyaluronic acid gel, the temperature of the cross-linking reaction is 20-50°C.

[0073] During the preparation of the cross-linked hyaluronic acid gel, the cross-linking reaction time is 2 to 32 hours.

[0074] In the preparation process of the cross-linked hyaluronic acid gel, the cross-linking reaction includes the following steps: a primary cross-linking is performed at 40 to 50° C. for 3 to 8 hours, and a secondary cross-linking is performed at 20 to 25° C. for 10 to 24 hours.

[0075] Preferably, the primary cross-linking temperature is 40-45°C.

[0076] Preferably, the time for the primary cross-linking is 3 to 6 hours, for example 4 hours.

[0077] Preferably, the primary cross-linking is performed under static conditions.

[0078] Preferably, the secondary cross-linking time is 10 to 15 hours, for example 12 hours.

[0079] Preferably, the secondary cross-linking is performed under static conditions.

[0080] During the preparation of the cross-linked hyaluronic acid gel, after the cross-linking reaction, the gel obtained after the cross-linking reaction may be further subjected to at least one of shearing into pieces, washing, diluting, granulating and sterilizing.

[0081] Preferably, the length, width and height of the sheared gel are independently 0.5 to 5 cm.

[0082] Preferably, the cleaning solution used in the cleaning is a saline solution, preferably a phosphate buffer solution.

[0083] More preferably, the osmotic pressure of the cleaning solution is 200-400 mOsm / L, more preferably 220-320 mOsm / L, for example 250 mOsm / L.

[0084] More preferably, the pH value of the cleaning solution is 6.0-8.0, for example 7.

[0085] More preferably, the mass ratio of the cleaning solution to the gel obtained after the cross-linking reaction can be conventional in the art, preferably (20-200):1.

[0086] Preferably, the total cleaning time is 1 to 96 hours, more preferably 8 to 72 hours.

[0087] Preferably, the cleaning can be performed in multiple times according to the conventional method in the art, and the number of cleaning times is 3 to 6 times.

[0088] Preferably, the cleaning can be performed in a semipermeable membrane.

[0089] Preferably, the granulation method comprises homogenization and / or sieving.

[0090] More preferably, the mesh size of the sieve plate is 100-250 meshes, more preferably 150-200 meshes.

[0091] Preferably, the sterilization method comprises autoclaving.

[0092] The present application also provides a method for preparing the injectable filling material as described above, which specifically comprises the following steps: uniformly mixing the components in the injectable filling material.

[0093] In some embodiments, the mixing operation may further include a degassing operation.

[0094] The degassing method may be a negative pressure degassing method commonly used in the art.

[0095] In a preferred embodiment, the injectable filling material includes the polyester microspheres, the cross-linked hyaluronic acid gel and the buffer; the mixing includes the following steps:

[0096] (a) mixing the buffer solution and the cross-linked hyaluronic acid gel to obtain a composite solution A;

[0097] (b) mixing the composite solution A with the polyester microspheres.

[0098] In a more preferred embodiment, the injectable filling material also includes non-cross-linked hyaluronic acid substances and / or anesthetics, and the step (a) includes the following steps: mixing the non-cross-linked hyaluronic acid substances and / or the anesthetics with the buffer solution, and then mixing them with the cross-linked hyaluronic acid gel to obtain a composite solution A.

[0099] The present application also provides a use of the injectable filling material as described above as a raw material in the preparation of medical or cosmetic products.

[0100] Among them, the medical or cosmetic products include filling and shaping products.

[0101] On the basis of conforming to the common sense in the art, the above-mentioned preferred conditions can be arbitrarily combined to obtain the preferred embodiments of the present application.

[0102] The reagents and raw materials used in this application are commercially available.

[0103] The positive progress of this application is that this application uses a combination of cross-linked hyaluronic acid gel with specific properties and polyester microspheres to successfully produce an injectable filling material that has both rapid onset and long-term effectiveness. In addition, the polyester microspheres have good dispersion in the system, and are not prone to problems such as needle blockage or inflammation during injection. The injection pushing force and cytotoxicity are both small, the use safety is high, the mechanical properties also meet the requirements, the filling effect is natural, and the aesthetics are high. BRIEF DESCRIPTION OF THE DRAWINGS

[0104] Figure 1 It is a comparison diagram of the injectable filling materials prepared in Example 1 and Comparative Example 3; wherein, the sample on the left is a diagram of the injectable filling material prepared in Example 1, and the sample on the right is a diagram of the injectable filling material prepared in Comparative Example 3. DETAILED DESCRIPTION

[0105] The present application is further described below by way of examples, but the present application is not limited to the scope of the examples. The experimental methods without specific conditions in the following examples are selected according to conventional methods and conditions, or according to the product instructions.

[0106] The reagents and raw materials used in the following examples are all commercially available, and the purity of the reagents used is injection grade.

[0107] The viscosity in this application is the viscosity measured at 25°C using a rotational viscometer.

[0108] The membrane emulsifier used in the following experiment 2 is a high-throughput SPG membrane emulsifier model KH-125 produced by SPG Corporation of Japan.

[0109] Experiment 1: Preparation of PLA-PEG-PLA block copolymers 1 to 6:

[0110] ① Weigh 1 kg of L-lactide and add it to the reactor, pass nitrogen protection, and adjust the temperature of the reactor to 110-130°C until the L-lactide is completely melted;

[0111] ② After L-lactide is completely melted, polyethylene glycol (see Table 1 for the amount added) and 1.3 g of stannous isooctanoate are injected into the reaction bottle, nitrogen is passed through to maintain a positive pressure in the system, the temperature is raised to 135°C, and the reaction is kept at this temperature for 24 hours; after recrystallization and drying, PLA-PEG-PLA block copolymer is obtained.

[0112] During the preparation of PLA-PEG-PLA block copolymers 1 to 6, the selected polyethylene glycol number average molecular weight, and the mass ratio of polyethylene glycol to L-lactide are shown in Table 1 below.

[0113] Table 1

[0114]

[0115] Experiment 2: Preparation of polyester microspheres

[0116] (① Preparation of aqueous phase: Add an appropriate amount of purified water to a container, slowly add 20 g of polyvinyl alcohol 1788, stir until completely dissolved, and adjust the volume to 1 L to obtain an aqueous phase with a viscosity of 7.5 mPa·s;

[0117] ② Preparation of organic phase: Add an appropriate amount of dichloromethane to a container, weigh 20 g of the PLA-PEG-PLA block copolymer 1 prepared above, add it to the container, stir to completely dissolve it and adjust the volume to 100 mL to obtain an organic phase;

[0118] ③ Membrane emulsification: slowly pour the above organic phase into the aqueous phase, use a membrane emulsifier to emulsify the mixed liquid, the membrane tube pore size is 40μm, the number of membrane passes is 1, and the emulsion is obtained;

[0119] ④ Solidification: Stir the emulsified emulsion and blow nitrogen to volatilize the dichloromethane until the dichloromethane is completely evaporated;

[0120] ⑤ Collection: After the dichloromethane is completely evaporated, the suspension is centrifuged to collect the solid components and dried to obtain spherical or elliptical polyester microspheres. The microspheres with a particle size of 20 to 50 μm account for 92.6%, D50 is 33.64 μm, and the particle size span is 0.78.

[0121] Experiment 3: Preparation of cross-linked hyaluronic acid gel

[0122] 1,4-Butanediol diglycidyl ether (the amount added is shown in Table 2) was added to a sodium hydroxide aqueous solution (the concentration and the amount added are shown in Table 2), and the mixture was uniformly mixed to obtain material A. 1 g of non-cross-linked sodium hyaluronate with a molecular weight of 130 WDa was weighed and added to material A. After uniform mixing, a primary cross-linking reaction was carried out at 40° C. and allowed to stand for 4 hours, and then a secondary cross-linking reaction was carried out at 25° C. and allowed to stand for 12 hours;

[0123] The gel obtained after the secondary cross-linking reaction was cut into suitable small pieces, and the sheared gel was washed with a phosphate buffer with an osmotic pressure of 250 mOsm / L and a pH of 7. The concentration of non-cross-linked sodium hyaluronate in the gel was adjusted to 20 mg / g, and the gel was passed through a sieve plate (the mesh size of the sieve plate is shown in Table 2) to obtain a cross-linked hyaluronic acid gel.

[0124] Table 2

[0125]

[0126] Preparation of Injectable Filling Materials in Examples and Comparative Examples

[0127] (① Weigh an appropriate amount of phosphate buffer solution with an osmotic pressure of 220-320 mOsm / L and a pH of 6.0-8.0 into a container, add 3 g of lidocaine hydrochloride, non-cross-linked sodium hyaluronate with a molecular weight of 130 WDa, and the cross-linked hyaluronic acid gel prepared in the above experiment 3, and stir evenly to obtain a composite gel;

[0128] ② Weigh the polyester microspheres obtained in the above test 2 and add them to the composite gel, and add the above phosphate buffer to a total mass of 1 kg. Turn on the stirring, stir and mix the sample for 3 to 5 hours, degas under negative pressure, and then pack them into pre-filled syringes and sterilize them with high-pressure steam to obtain an injectable filling material. The total amount of each component added is shown in Table 3 below.

[0129] Table 3

[0130]

[0131] Effect Example 1

[0132] (1) The number average molecular weight of the PLA-PEG-PLA block copolymers 1 to 6 prepared in the above experiment 1 was tested. The results are shown in Table 4.

[0133] (2) The PLA-PEG-PLA block copolymers 1 to 6 in the above experiment 1 were respectively made into polyester microspheres as test samples using the following preparation process, and the changes in the pH value and lactic acid content of the system before and after sterilization of the test samples were tested.

[0134] Preparation method of samples to be tested:

[0135] ① Preparation of aqueous phase: Add 30 g of polyvinyl alcohol 1788 into an appropriate amount of purified water, stir until completely dissolved, and adjust the volume to 1 L to obtain an aqueous phase with a viscosity of 12 mPa·s;

[0136] ② Preparation of organic phase: Add 20 g of any one of PLA-PEG-PLA block copolymers 1 to 6 into an appropriate amount of dichloromethane, stir to completely dissolve it and adjust the volume to 100 mL to obtain an organic phase;

[0137] ③ Emulsification: slowly pour the above organic phase into the aqueous phase, mechanically stir and emulsify to obtain an emulsion;

[0138] ④ Solidification: Stir the emulsified emulsion to completely evaporate the dichloromethane in the system;

[0139] ⑤ Collection: After the dichloromethane is completely evaporated, the suspension is centrifuged to collect the solid components, which are then dried to obtain injectable filled microspheres.

[0140] pH value test method before and after sterilization: Take 1g of the sample prepared above, add it to an injection bottle, add 4mL of phosphate buffer with a pH value of 7.0 (pH value of the system before sterilization) to the bottle, mix well and sterilize with high-pressure steam, test the pH value of the system after sterilization, and compare the changes in pH value of the system before and after sterilization. The results are shown in Table 4.

[0141] Table 4

[0142]

[0143]

[0144] Test method for lactic acid content in the system before and after sterilization: Take 1 g of the sample prepared above, add it to an injection bottle, add 4 mL of phosphate buffer with a pH value of 7.0 to the bottle, mix well and then sterilize with high-pressure steam, test the lactic acid content in the system before and after sterilization, and calculate the change in lactic acid content. The results are shown in Table 5.

[0145] Table 5

[0146] Raw materials to be tested Changes in lactic acid content in the system before and after sterilization PLA-PEG-PLA block copolymer 1 0.057mg / mL PLA-PEG-PLA block copolymer 2 0.085mg / mL PLA-PEG-PLA block copolymer 3 0.029mg / mL PLA-PEG-PLA block copolymer 5 0.049mg / mL PLA-PEG-PLA block copolymer 6 0.270mg / mL

[0147] The results showed that the PLA-PEG-PLA block copolymer prepared above had ideal thermal stability, and the pH value of the system and the lactic acid content in the system changed little before and after sterilization.

[0148] Effect Example 2 Performance Test of Cross-linked Hyaluronic Acid Gel

[0149] The elastic modulus G', viscous modulus G", shear viscosity η and particle size distribution of the cross-linked hyaluronic acid gels 1 to 4 obtained in the above experiment 3 were tested. The results are shown in Table 6 below.

[0150] (1) Elastic modulus G' and viscous modulus G" test method: Use a rheometer to perform dynamic frequency scanning, set the test temperature to 25°C, and the frequency variation range to 0.1-10 Hz. Compare the values ​​of the elastic modulus G' and the viscous modulus G" at 1 Hz.

[0151] (2) Shear viscosity η test method: Use a rheometer to perform shear rate scanning, set the detection temperature to 25°C, and the shear rate range to 0.1s -1 ~100s -1 , take the shear rate as 1s -1 Shear viscosity value under certain conditions.

[0152] The particle size distribution was tested using a laser particle size analyzer, and D10, D50 and D90 were counted.

[0153] Table 6

[0154]

[0155]

[0156] Effect Example 3

[0157] The elastic modulus G', viscous modulus G", complex viscosity η*, shear viscosity η, cytotoxicity and pushing force of the injectable filling materials prepared in the above Examples 1 to 5 and Comparative Examples 1 to 4 were tested. The results are shown in Table 7.

[0158] (1) Elastic modulus G' and viscous modulus G" test method: Use a rheometer to perform dynamic frequency scanning, set the test temperature to 25°C, and the frequency variation range to 0.1-10 Hz. Compare the values ​​of the elastic modulus G' and the viscous modulus G" at 1 Hz.

[0159] (2) Shear viscosity η test method: Use a rheometer to perform shear rate scanning, set the detection temperature to 25°C, and the shear rate range to 0.1s -1 ~100s -1 , take the shear rate as 1s -1 Shear viscosity value under certain conditions.

[0160] (3) Cytotoxicity test method:

[0161] Preparation of the test solution: Take 2 g of the injectable filling material prepared in the above examples or comparative examples, add it to 10 mL of cell culture medium, extract it under shaking conditions, let it stand for 2 hours after extraction, and take the supernatant as the test solution.

[0162] Collect L929 cells with good growth status and adjust the density to 1×10 5 cells / mL. 100 μL of the above cell suspension was inoculated into each well of a 96-well cell culture plate, and cultured in a cell culture incubator at 37°C and 5% CO2 for 24 hours to form a nearly confluent monolayer of cells. The 96-well plate was observed under a microscope to ensure that the cells were evenly distributed in the microwells. The original culture medium was aspirated, and 100 μL of the test solution was added to each well of the experimental group, and 100 μL of cell culture solution was added to each well of the blank group. The plates were cultured in a cell culture incubator at 37°C and 5% CO2 for 24 hours, and the cell status of each plate well was observed under a microscope. The old culture medium was carefully removed, and 50 μL of MTT solution was added to each well. The plate was placed in a cell culture incubator and cultured for 2 hours again, and the liquid MTT solution in the well was discarded. 100 μL of isopropanol was added to each well. After shaking and dissolving, the absorbance value was measured at 570 nm (reference wavelength 650 nm) on an ELISA reader, and the cell survival rate was calculated. The results are shown in Table 7.

[0163] Cell survival rate % = 100 × OD 570e / OD 570b

[0164] OD 570e : Average absorbance of the experimental group;

[0165] OD 570b : Average absorbance of blank group.

[0166] (4) Pushing force test method: Take one filled sample, install a Terumo 27G (0.4*12mm) needle, remove all bubbles from the needle, place it in the detector of a universal tensile tester, and test at a speed of 30mm / min to test the maximum pushing force and average pushing force. The results are shown in Table 7.

[0167] Table 7

[0168]

[0169] The injectable filling materials prepared in the above embodiments 1 to 5 simultaneously meet the requirements of rapid onset and long-term effectiveness, and the mechanical properties meet the use requirements, the filling effect is natural, and the aesthetics is high; the polyester microspheres have good dispersibility in the system, small pushing force, and are not prone to problems such as needle blockage or inflammation during injection; the cytotoxicity is low, the use safety is high, and the difficulty of injection is reduced.

[0170] According to the results of Comparative Example 1, when the amount of polyester microspheres added to the injectable filling material is too high, it will lead to excessive pushing force, affecting hand fit and making injection difficult; it will also lead to uneven material distribution during the injection process, affecting the filling effect and aesthetics.

[0171] According to the results of Comparative Example 2, when the addition amount of non-cross-linked sodium hyaluronate is too high, the cytotoxicity is greater and the safety of use is reduced.

[0172] According to the results of Comparative Examples 3 and 4, when the type of cross-linked hyaluronic acid gel is not properly selected, the stability and viscoelasticity of the injectable filling material will be affected. For example, the particle size distribution of the cross-linked hyaluronic acid gel used in Comparative Example 3 is relatively large, resulting in poor dispersion of the polyester microspheres in the injectable filling material system and uneven preparation (attached Figure 1 The left side of the middle is the injectable filling material prepared in Example 1, and the right side is the injectable filling material prepared in Comparative Example 3). It is easy to cause needle blockage or large pushing force during injection, which makes injection difficult and also affects the filling effect and aesthetics. The cross-linked hyaluronic acid gel used in Comparative Example 4 has a large elastic modulus, resulting in a large elastic modulus of the injectable filling material finally prepared, which is not easy to shape and deform, and is unnatural after injection and has a stiff feeling; it is not easy to be dispersed in the tissue after injection, which can cause inflammation.

[0173] Finally, it should be noted that in this application, the terms "comprises", "includes" or any other variations thereof are intended to cover non-exclusive inclusion, so that a process, method, article or apparatus that includes a series of elements includes not only those elements, but also other elements that are not explicitly listed, or also includes elements that are inherent to such process, method, article or apparatus.

[0174] Although the present application has been disclosed above through the description of the specific embodiments of the present application, it should be understood that those skilled in the art can design various modifications, improvements or equivalents to the present application within the spirit and scope of the attached scheme. These modifications, improvements or equivalents should also be considered to be included in the scope of protection claimed in the present application.

Claims

1. An injectable filling material, characterized in that: It comprises hyaluronic acid substances and polyester microspheres; the hyaluronic acid substances are cross-linked hyaluronic acid gels, or are composed of cross-linked hyaluronic acid gels and non-cross-linked hyaluronic acid substances; Among them, the mass ratio of HA in the hyaluronic acid substance to the mass ratio of the polyester microspheres is 1:(2-25); the mass ratio of HA in the cross-linked hyaluronic acid gel to the non-cross-linked hyaluronic acid substance is 1:(0-0.5); the elastic modulus G` of the cross-linked hyaluronic acid gel at 1 Hz is 100-600 Pa; the particle size D50 of the cross-linked hyaluronic acid gel is 200-500 μm.

2. The injectable filling material according to claim 1, characterized in that The injectable filling material satisfies at least one of the following conditions (1) to (15): (1) The mass ratio of HA in the hyaluronic acid substance to the mass ratio of the polyester microspheres is 1:(10-25), preferably 1:(10-17); (2) The mass ratio of HA in the cross-linked hyaluronic acid gel to the non-cross-linked hyaluronic acid substance is 1:(0-0.4), preferably 1:(0-0.3); (3) The concentration of HA in the cross-linked hyaluronic acid gel is 15 to 30 mg / g, preferably 18 to 25 mg / g; (4) The elastic modulus G' of the cross-linked hyaluronic acid gel at 1 Hz is 100 to 500 Pa, preferably 250 to 350 Pa; (5) The viscosity modulus G`` of the cross-linked hyaluronic acid gel at 1 Hz is 20 to 100 Pa, preferably 20 to 40 Pa; (6) The cross-linked hyaluronic acid gel is -1 The shear viscosity η at the shear rate is 40 to 100 Pa·s; (7) The particle size D50 of the cross-linked hyaluronic acid gel is 250 to 350 μm; (8) The particle size D10 of the cross-linked hyaluronic acid gel is 100-200 μm, preferably 140-170 μm; (9) The particle size D90 of the cross-linked hyaluronic acid gel is 400-700 μm, preferably 400-600 μm; (10) The non-cross-linked hyaluronic acid substance is non-cross-linked hyaluronic acid and / or non-cross-linked hyaluronate; (11) The molecular weight of the non-cross-linked hyaluronic acid substance is 10 WDa to 300 WDa, preferably 50 to 200 WDa; (12) The polyester microspheres have a particle size of 20 to 50 μm accounting for more than 80%, preferably more than 90%; (13) The particle size D50 of the polyester microspheres is 20 to 50 μm, preferably 30 to 40 μm; (14) The material of the polyester microspheres is at least one selected from polylactic acid, polycaprolactone, polyhydroxyalkanoate, PLA-PEG block copolymer, PLA-PEG-PLA block copolymer and PCL-PEG block copolymer; (15) The injectable filling material also includes a buffer and / or an anesthetic; preferably, the buffer is a phosphate buffer; more preferably, the phosphate buffer includes dihydrogen phosphate and dihydrogen phosphate; preferably, the osmotic pressure of the buffer is 220-320 mOsm / L; preferably, the pH value of the buffer is 6.0-8.0; preferably, the anesthetic is selected from at least one of lidocaine hydrochloride, lidocaine carbonate, tetracaine, prilocaine, procaine, mepivacaine and bupivacaine; preferably, the mass percentage of the anesthetic in the injectable filling material is 0.1%-0.5%.

3. The injectable filling material according to claim 2, characterized in that The preparation method of the polyester microspheres comprises the following steps: assembling the polyester microsphere materials into microspheres by an emulsified solvent volatilization method; Preferably, the method for preparing the polyester microspheres comprises the following steps: the organic phase comprises the material of the polyester microspheres and an organic solvent; the aqueous phase comprises a surfactant and water; the organic phase and the aqueous phase are mixed, emulsified, and solidified to obtain the polyester microspheres.

4. The injectable filling material according to claim 3, characterized in that The preparation method of the polyester microspheres satisfies at least one of the following conditions (1) to (9): (1) The organic solvent is selected from halogenated alkane solvents and / or ester solvents; preferably, the halogenated alkane solvent is a chlorinated alkane solvent, more preferably selected from dichloromethane and / or chloroform; preferably, the ester solvent is a C2-C6 alkyl acetate, more preferably ethyl acetate; (2) The mass volume ratio of the polyester microsphere material to the organic solvent is 80 to 350 g / L; (3) The volume ratio of the organic phase to the aqueous phase is 1:(3-20), preferably 1:(5-15); (4) The surfactant is polyvinyl alcohol, preferably polyvinyl alcohol 1788; (5) The mass volume ratio of the surfactant to the water is 8 to 45 g / L; (6) The viscosity of the aqueous phase is 4 to 25 mPa·s; (7) The water is purified water; (8) The emulsification method includes mechanical stirring emulsification, membrane emulsification or homogenization emulsification; (9) The curing method includes a reduced pressure volatilization method and / or an air flow blowing method.

5. The injectable filling material according to claim 2, characterized in that The material of the polyester microspheres is PLA-PEG-PLA block copolymer; Preferably, the number average molecular weight of the PLA-PEG-PLA block copolymer is 40,000 to 130,000, more preferably 40,000 to 120,000, and even more preferably 40,000 to 90,000; Preferably, the number average molecular weight of PEG in the PLA-PEG-PLA block copolymer is 100 to 800, more preferably 200 to 800; Preferably, the PLA in the PLA-PEG-PLA block copolymer is selected from at least one of L-polylactic acid, D-polylactic acid and racemic polylactic acid.

6. The injectable filling material according to any one of claims 1 to 5, characterized in that: The preparation method of the cross-linked hyaluronic acid gel comprises the following steps: mixing a cross-linking agent, a non-cross-linked hyaluronic acid substance and an alkaline aqueous solution, and obtaining the cross-linked hyaluronic acid gel through a cross-linking reaction; wherein the cross-linking agent is a cross-linking agent containing at least two epoxy groups; the volume mass ratio of the cross-linking agent to the non-cross-linked hyaluronic acid substance is 1.5 to 25 μL / g; the mass ratio of the non-cross-linked hyaluronic acid substance to the alkaline aqueous solution is (0.16 to 0.4): 1; the mass percentage of the alkaline substance in the alkaline aqueous solution is 0.8% to 2%.

7. The injectable filling material according to claim 6, characterized in that The preparation method of the cross-linked hyaluronic acid gel satisfies at least one of the following conditions (1) to (9): (1) The crosslinking agent is selected from a crosslinking agent containing two epoxy groups, preferably at least one selected from 1,4-butanediol diglycidyl ether, ethylene glycol diglycidyl ether, neopentyl glycol diglycidyl ether, polyethylene glycol diglycidyl ether, polypropylene glycol diglycidyl ether and poly(dimethylsiloxane) diglycidyl ether; (2) The volume mass ratio of the cross-linking agent to the non-cross-linked hyaluronic acid substance is 5 to 25 μL / g, preferably 10 to 20 μL / g; (3) The non-cross-linked hyaluronic acid substance is selected from non-cross-linked hyaluronic acid and / or non-cross-linked hyaluronate; preferably, the non-cross-linked hyaluronate is selected from at least one of non-cross-linked sodium hyaluronate, non-cross-linked potassium hyaluronate, non-cross-linked calcium hyaluronate and non-cross-linked zinc hyaluronate; (4) The molecular weight of the non-cross-linked hyaluronic acid substance is 50 WDa to 200 WDa, preferably 60 WDa to 200 WDa; (5) The mass ratio of the non-cross-linked hyaluronic acid substance to the alkaline aqueous solution is (0.18-0.4):1, preferably (0.2-0.4):1; (6) the alkaline aqueous solution is selected from at least one of a sodium hydroxide aqueous solution, a potassium hydroxide aqueous solution, a sodium carbonate aqueous solution and a sodium bicarbonate aqueous solution; (7) The water in the alkaline aqueous solution includes at least one of deionized water, distilled water, purified water and water for injection; (8) During the preparation of the cross-linked hyaluronic acid gel, the temperature of the cross-linking reaction is 20 to 50°C; the time of the cross-linking reaction is 2 to 32 hours; preferably, the cross-linking reaction comprises the following steps: a primary cross-linking at 40 to 50°C for 3 to 8 hours, and a secondary cross-linking at 20 to 25°C for 10 to 24 hours; (9) After the cross-linking reaction, the gel obtained after the cross-linking reaction is further subjected to at least one of shearing, washing, diluting, granulating and sterilizing. Preferably, the granulation method comprises homogenizing and / or sieving. More preferably, the mesh size of the sieve is 100 to 250, preferably 150 to 200.

8. A method for preparing an injectable filling material according to any one of claims 1 to 7, characterized in that: The preparation method comprises the following steps: uniformly mixing the components in the injectable filling material.

9. The method for preparing an injectable filling material according to claim 8, characterized in that: The preparation method satisfies the following conditions (1) and / or (2): (1) The mixing operation also includes a degassing operation; preferably, the degassing method is a negative pressure degassing method; (2) The injectable filling material comprises the polyester microspheres, the cross-linked hyaluronic acid gel and the buffer solution; the mixing comprises the following steps: (a) mixing the buffer solution and the cross-linked hyaluronic acid gel to obtain a composite solution A; (b) mixing the composite solution A with the polyester microspheres; preferably, the injectable filling material also comprises a non-cross-linked hyaluronic acid substance and / or an anesthetic, and the step (a) comprises the following steps: mixing the non-cross-linked hyaluronic acid substance and / or the anesthetic with the buffer solution, and then mixing with the cross-linked hyaluronic acid gel to obtain a composite solution A.

10. An injectable filling material, characterized in that: The injectable filling material is prepared by the method for preparing the injectable filling material as claimed in claim 8 or 9.

11. Use of the injectable filling material according to any one of claims 1 to 7 or the injectable filling material according to claim 10 as a raw material in the preparation of medical or cosmetic products.

Citation Information

Cited By

  • Preparation method of compound collagen filler for injection

    CN119656385A

  • Injectable filler as well as preparation method and application thereof

    CN120242148A

  • Sodium hyaluronate gel regeneration filler for injection as well as preparation method and application of sodium hyaluronate gel regeneration filler

    CN121754729A